<p>CONSUN PHARMA (01681.HK) announced its full-year results for the year ended December last year, with revenue of RMB 3.417 billion, an increase of 15.2% year-on-year. Net profit was RMB 1.078 billion, an increase of 18.4% year-on-year; earnings per share were RMB 1.27. A final dividend of HKD 0.4 was declared, compared to HKD 0.3 in the same period last year</p>

512290

513060

159316

<p>CONSUN PHARMA announced its full-year results for the year ended last December, with revenue of RMB 3.417 billion, an increase of 15.2% year-on-year. Net profit was RMB 1.078 billion, an increase of 18.4% year-on-year; earnings per share were RMB 1.27. A final dividend of HKD 0.4 was declared, compared to HKD 0.3 in the same period last year</p>

AASTOCKS

Guotai CSI Bio-medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP CSI Pharmaceuticals ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

CONSUN PHARMA

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

"Performance" CONSUN PHARMA's annual net profit is RMB 1.078 billion, an increase of 18.4%, with a final dividend of HKD 0.4